{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-114908","form_type":"8-K","ticker":"NUVB","cik":"0001811063","company_name":"Nuvation Bio Inc.","filed_at":"2025-05-07T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.821393+00:00","generated_at":"2026-05-22T08:43:52.180666+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Nuvation Bio Q1 net loss $53.2M; cash $461.7M; taletrectinib PDUFA June 23, 2025","bullets":["Net loss of $53.2M ($0.16/share) vs $14.8M ($0.07) in Q1 2024; R&D rose to $24.6M, SG&A to $35.4M.","Cash, equivalents and marketable securities $461.7M as of March 31, 2025.","FDA Priority Review for taletrectinib NDA on track; PDUFA goal date June 23, 2025.","Secured up to $250M non-dilutive financing from Sagard Healthcare; $150M royalty and $50M debt upon FDA approval.","Appointed Stephen Dang, Ph.D., as Senior Vice President, General Counsel in March 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-114908","json":"https://secwatch.observer/filing/0001193125-25-114908.json","markdown":"https://secwatch.observer/filing/0001193125-25-114908.md","text":"https://secwatch.observer/filing/0001193125-25-114908.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1811063/000119312525114908/0001193125-25-114908-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1811063/000119312525114908/d905090d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-22T08:43:52.180666+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}